Olema Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $742.67M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 16, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 18, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 11, 2024 | After market close | – | – | – |
Press releases
Announcements Olema Pharmaceuticals filed with the SEC
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Olema Oncology Reports First Quarter 2026 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Advancing medicines for breast cancer and beyond Corporate Overview January 2025
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Olema Oncology Reports Third Quarter 2025 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Advancing medicines for breast cancer and beyond Corporate Overview October 2025
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Olema Oncology Reports Second Quarter 2025 Financial and Operating Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Advancing medicines for breast cancer and beyond Corporate Overview August 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Olema Oncology Reports First Quarter 2025 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Advancing medicines for breast cancer and beyond Corporate Overview March 2025 EXHIBIT 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Advancing medicines for breast cancer and beyond Corporate Overview January 2025 EXHIBIT 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Palazestrant in Combination with Ribociclib Clinical Update SABCS 2024 December 10, 2024 EXHIBIT 99.3
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Advancing medicines for breast cancer and beyond Corporate Overview September 2024
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ESMO Breast Cancer 2024 Palazestrant-Ribociclib Combination Interim Results May 15, 2024
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Olema Oncology JP Morgan Conference January 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Olema SABCS December 2023 Presentation December 6, 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
scope, progress, results and costs of developing our product candidate or any other future product candidates, expected manufacturing capabilities, strategy, regulatory matters, including the timing
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K/A
Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Olema Oncology Announces Expansion of Collaboration
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K